Crossmark

Maximum tumor diameter and renal function can predict the declining surface dose rate after 177Lu-Dotatate: preliminary results of single institution in Japan

Crossref DOI link: https://doi.org/10.1007/s11604-024-01585-5

Published Online: 2024-05-10

Published Print: 2024-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Ono, Takashi https://orcid.org/0000-0002-9711-1158
Ichikawa, Mayumi

Tanada, Takeo

Kanezawa, Chika

Sato, Hiraku
License Information

Text and Data Mining valid from 2024-05-10

Version of Record valid from 2024-05-10
More Information

Article History

Received: 20 March 2024

Accepted: 27 April 2024

First Online: 10 May 2024

Declarations

:

: The authors declare no conflict of interest.

: This prospective study was approved by the Institutional Ethics Committee of the Faculty of Medicine at Yamagata University (approval number: 2021-297). The study was conducted in accordance with the principles of the Declaration of Helsinki.

: All patients agreed to this prospective observational study.

Document is current

Any future updates will be listed below